Literature DB >> 7688167

Expression of p53 product in Chinese human bladder carcinoma.

D W Ye1, J F Zheng, S X Qian, Y J Ma.   

Abstract

Expression of p53 protein was examined in 67 cases of primary transitional cell carcinoma of the bladder and 6 normal controls using an immunohistochemical method on paraffin sections. Positive nuclear staining for p53 in malignant cells was found in 34 (51%) of the 67 cancer patients; no positive staining for p53 was detected in any of the normal controls or in the benign cells, including stromal and inflammatory cells, within the tumor tissue. There were 8 positive cases (33%) in 24 grade G1 tumors, 12 (48%) in 25 G2 tumors and 14 (78%) in 18 G3 tumors. p53 protein was detected positively in 14 (36%) of 39 superficial tumors (Tis-T1) and in 20 (71%) of 28 invasive tumors (T2-T4). Thus, positive staining for p53 was found more frequently in poorly differentiated tumors (chi-squared test: G3/G1 + G2 P < 0.01) and in invasive tumors (chi-squared test: T2-T4/Tis-T1 P < 0.01). Expression of p53 was also closely associated with recurrence of tumors. Alterations in p53 expression may be of prognostic value in cases of bladder transitional cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7688167     DOI: 10.1007/bf00590040

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  33 in total

1.  T antigen is bound to a host protein in SV40-transformed cells.

Authors:  D P Lane; L V Crawford
Journal:  Nature       Date:  1979-03-15       Impact factor: 49.962

2.  Allele loss on short arm of chromosome 17 in breast cancers.

Authors:  J Mackay; C M Steel; P A Elder; A P Forrest; H J Evans
Journal:  Lancet       Date:  1988-12-17       Impact factor: 79.321

3.  Meth A fibrosarcoma cells express two transforming mutant p53 species.

Authors:  D Eliyahu; N Goldfinger; O Pinhasi-Kimhi; G Shaulsky; Y Skurnik; N Arai; V Rotter; M Oren
Journal:  Oncogene       Date:  1988-09       Impact factor: 9.867

4.  Expression of the p53 protein during the cell cycle of human peripheral blood lymphocytes.

Authors:  W E Mercer; R Baserga
Journal:  Exp Cell Res       Date:  1985-09       Impact factor: 3.905

5.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

6.  Mutant p53 proteins bind hsp 72/73 cellular heat shock-related proteins in SV40-transformed monkey cells.

Authors:  H W Stürzbecher; P Chumakov; W J Welch; J R Jenkins
Journal:  Oncogene       Date:  1987-05       Impact factor: 9.867

7.  High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene.

Authors:  A Lavigueur; V Maltby; D Mock; J Rossant; T Pawson; A Bernstein
Journal:  Mol Cell Biol       Date:  1989-09       Impact factor: 4.272

8.  Archival analysis of p53 genetic and protein alterations in Chinese esophageal cancer.

Authors:  W P Bennett; M C Hollstein; A He; S M Zhu; J H Resau; B F Trump; R A Metcalf; J A Welsh; C Midgley; D P Lane
Journal:  Oncogene       Date:  1991-10       Impact factor: 9.867

9.  Allelic losses of chromosomes 9, 11, and 17 in human bladder cancer.

Authors:  Y C Tsai; P W Nichols; A L Hiti; Z Williams; D G Skinner; P A Jones
Journal:  Cancer Res       Date:  1990-01-01       Impact factor: 12.701

10.  Increased expression of mutant forms of p53 oncogene in primary lung cancer.

Authors:  R Iggo; K Gatter; J Bartek; D Lane; A L Harris
Journal:  Lancet       Date:  1990-03-24       Impact factor: 79.321

View more
  2 in total

1.  The relation of mutant p53 accumulation in transitional cell carcinoma of bladder with pathological stage, grade, recurrence and survival.

Authors:  C O Yeniyol; T Süelözgen; E Vardar; S Sural; H Postaci; A R Ayder
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

2.  Spotlight on differentially expressed genes in urinary bladder cancer.

Authors:  Apostolos Zaravinos; George I Lambrou; Dimitrios Volanis; Dimitris Delakas; Demetrios A Spandidos
Journal:  PLoS One       Date:  2011-04-05       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.